Trump Links Prenatal Tylenol to Autism; Experts Push Back

President Trump and HHS officials announced a link between prenatal acetaminophen (Tylenol/paracetamol) use and autism, urged pregnant women to avoid the drug when possible, and said the FDA would notify clinicians and pursue a label change; the administration also highlighted potential therapies such as leucovorin. Medical experts, professional societies and advocacy groups strongly pushed back, saying observational studies do not prove causation and that public guidance should be grounded in robust science. Co‑authors of a review cited by the administration and other researchers recommended “judicious” use— the lowest effective dose for the shortest duration under medical supervision—rather than blanket avoidance because untreated fever and pain can harm pregnancy. UK regulators and national health officials reassured expectant mothers that paracetamol remains the recommended first‑line option in pregnancy when needed. The announcement prompted public concern, with many pregnant people contacting pharmacies and health providers and sparking debate about public messaging and the interpretation of autism research.